Recruiting

Testing a new injection to boost immune response in people with HIV

Plain-English translation of NCT07579741 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing JL18008, a new injectable medication designed to boost immune function in people living with HIV who have been on stable HIV medications for many years but whose immune systems have not fully recovered. Researchers want to see if adding this medication to your current HIV treatment can help strengthen your immune system and improve your health. The study will test three different dose levels to find the safest and most effective option.

Some people with HIV maintain an undetectable viral load (meaning the virus is controlled) but their immune system doesn't bounce back to normal levels, even after years of successful treatment. This medication may offer a new way to help their immune systems recover and function better.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been on HIV medications for at least 4 years with a stable treatment plan for at least 3 months
your viral load has been undetectable (below 50 copies) for at least 3 years
your CD4 count (a key immune marker) has stayed at 350 cells or below, measured multiple times over the past 4 years
you are willing to use effective contraception and commit to the study visits and procedures

You likely don't qualify if…

you are allergic to any ingredient in the study medication
you have taken immune-suppressing medications or certain hormone therapies in the past 3 months
you have a severe autoimmune disease or active infection requiring treatment
you have uncontrolled high blood pressure, recent heart problems, or positive tests for hepatitis B or C
you have abnormal blood work results, including low red blood cells, low white blood cells, or low platelets

What participation looks like

If you join this study, you will continue taking your regular HIV medications without any changes. You will receive weekly injections of either the new medication or a placebo (inactive injection) for 4 weeks, given directly into your muscle. You'll be randomly assigned to one of three dose groups, and neither you nor the researchers will know which group you're in. After the 4 weeks of injections, you'll have follow-up visits to monitor your immune system, safety, and overall health.

AI-generated summary from trial data · Aug 7, 2026 · Not medical advice

Testing a new injection to boost immune response in people with HIV

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)